LENZ Therapeutics, Inc.LENZNASDAQ
Loading
SG&A Expense Growth Recovery in ProgressRecovering
Percentile Rank67
5Y CAGR-56.9%
Year-over-Year Change
Year-over-year SG&A expense growth
5Y CAGR
-56.9%/yr
Long-term compound
Percentile
P67
Within normal range
vs 5Y Ago
0x
Contraction
Streak
1 yr
Consecutive growthRecovering
| Period | Value |
|---|---|
| 2025 | 216.99% |
| 2024 | 122.44% |
| 2023 | 196.58% |
| 2022 | -79.99% |
| 2021 | 411.68% |
| 2020 | 14575.86% |
| 2019 | 0.00% |